Literature DB >> 12214010

Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway.

Xue-Qing Chen1, John R. Fawcett, Yueh-Erh Rahman, Thomas A. Ala, William H. Frey II.   

Abstract

Purpose: To assess the potential of delivering nerve growth factor (NGF) to the brain along the olfactory neural pathway for the treatment of Alzheimer's disease.
Methods: Recombinant human NGF (rhNGF) was given as nose drops to anesthetized rats. The rhNGF concentrations in the brain were determined by enzyme-linked immunosorbent assay (ELISA).
Results: Following olfactory administration, rhNGF reached the brain within an hour, achieving a concentration of 3400 pM in the olfactory bulb, 660–2200 pM in other brain regions and, 240 pM and 180 pM in the hippocampus and the amygdala, respectively. In contrast, little or no rhNGF was found in the brain following intravenous administration. Conclusions: A significant amount of rhNGF can be delivered to the brain via the olfactory pathway. The detection of rhNGF by ELISA indicates that rhNGF is delivered to the brain relatively intact. The rapid appearance of rhNGF in the brain suggests that it may be transported by an extraneuronal route into the brain via intercellular clefts in the olfactory epithelium. Further work to clarify the transport mechanism is underway. The olfactory pathway is a promising, non-invasive route for drug delivery to the brain, which has potential for the treatment of neurodegenerative diseases including Alzheimer's disease.

Entities:  

Year:  1998        PMID: 12214010     DOI: 10.3233/jad-1998-1102

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  54 in total

1.  Effects of pineal-gland peptides on the electric activity of pinealocytes in rats.

Authors:  D A Sibarov; R I Kovalenko; A D Nozdrachev; V V Malinin; V Kh Khavinson
Journal:  Dokl Biol Sci       Date:  2002 Jul-Aug

Review 2.  The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders.

Authors:  D S Quintana; A J Guastella; L T Westlye; O A Andreassen
Journal:  Mol Psychiatry       Date:  2015-11-10       Impact factor: 15.992

Review 3.  On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease.

Authors:  Simona Capsoni; Antonino Cattaneo
Journal:  Cell Mol Neurobiol       Date:  2006-08-31       Impact factor: 5.046

4.  Enhancement of nose-brain delivery of therapeutic agents for treating neurodegenerative diseases using peppermint oil.

Authors:  S R Kiran Vaka; S Narasimha Murthy
Journal:  Pharmazie       Date:  2010-09       Impact factor: 1.267

5.  Intranasal drug delivery: a novel approach.

Authors:  Yashpal Chugh; Pragati Kapoor; A K Kapoor
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2009-04-25

6.  Intranasal delivery of a peptide with antidepressant-like effect.

Authors:  Virginia Brown; Fang Liu
Journal:  Neuropsychopharmacology       Date:  2014-03-17       Impact factor: 7.853

Review 7.  Oxytocin and social motivation.

Authors:  Ilanit Gordon; Carina Martin; Ruth Feldman; James F Leckman
Journal:  Dev Cogn Neurosci       Date:  2011-10       Impact factor: 6.464

Review 8.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

9.  Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice.

Authors:  Leah R Hanson; Jared M Fine; Dan B Renner; Aleta L Svitak; Rachel B Burns; Thuhien M Nguyen; Nathan J Tuttle; Dianne L Marti; S Scott Panter; William H Frey
Journal:  Drug Deliv Transl Res       Date:  2012-06       Impact factor: 4.617

10.  Effects of intranasal administration of epitalon on neuron activity in the rat neocortex.

Authors:  D A Sibarov; A B Vol'nova; D S Frolov; A D Nozdrachev
Journal:  Neurosci Behav Physiol       Date:  2007-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.